
|Videos|May 3, 2022
Dr. Munver on mitomycin gel for low-grade UTUC
Author(s)Urology Times staff
“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.
Advertisement
Ravi Munver, MD, vice chairman, chief, Minimally Invasive and Robotic Urologic Surgery, Department of Urology, Hackensack University Medical Center, discusses the treatment breakthrough of mitomycin gel (Jelmyto) as a therapy for patients with low-grade upper tract urothelial carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
4
Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer
5











